Canopy Growth (NASDAQ:CGC) Releases Earnings Results, Misses Expectations By $0.05 EPS

Canopy Growth (NASDAQ:CGC) announced its earnings results on Friday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05), Zacks reports. The company had revenue of $57.28 million for the quarter, compared to analysts’ expectations of $57.72 million. Canopy Growth had a negative net margin of 65.33% and a negative return on equity of 21.91%.

Here are the key takeaways from Canopy Growth’s conference call:

• Q2 consolidated revenue rose 22% to CAD 81.4 million, with cannabis revenue up 30%. International cannabis revenue surged 141% year over year to CAD 12.3 million, while Canadian medical and adult-use revenue also grew.
• Canopy reported an Adjusted EBITDA loss of CAD 2.9 million, an improvement from Q1, and said it remains on track for positive Adjusted EBITDA in the second half of fiscal 2027. It ended the quarter with CAD 320 million in cash and short-term investments, though adjusted gross margin fell to 31% from 33% a year earlier, partly due to lower Veterans Affairs Canada reimbursement.
• The company expects cultivation changes at Kincardine to lift flower production by at least 25%–30% within the existing footprint. Management expects improvements to become more visible as fiscal 2027 ends, with the full impact anticipated in fiscal 2028.
• New EU GMP certification at Smiths Falls, alongside renewed certification at Kincardine, gives Canopy an end-to-end certified supply chain and a path to offer more product categories in Europe. Management sees international markets as a key growth opportunity, but said new products are likely to have more impact starting in fiscal 2028.
• Storz & Bickel revenue declined 4% year over year to CAD 15.1 million as consumer spending remained variable amid economic uncertainty. The segment’s gross margin improved to 39% from 38%, and management expects a seasonally stronger Q3.

Canopy Growth Trading Down 3.6%

Shares of CGC opened at $0.65 on Friday. The company has a market capitalization of $292.72 million, a P/E ratio of -1.28 and a beta of 0.87. Canopy Growth has a one year low of $0.58 and a one year high of $2.38. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.39 and a current ratio of 3.04. The stock has a 50-day moving average price of $0.84 and a 200 day moving average price of $0.99.

Key Stories Impacting Canopy Growth

Here are the key news stories impacting Canopy Growth this week:

• Positive Sentiment: Net revenue increased 22% year over year, led by a 141% rise in international cannabis markets, indicating stronger sales despite the overall revenue miss. Canopy Growth Q2 results
• Positive Sentiment: Management said Kincardine flower output is targeted to rise 25%–30% and reiterated its expectation for positive adjusted EBITDA in the second half of fiscal 2027. These goals could support a recovery if achieved. Kincardine output and EBITDA outlook
• Negative Sentiment: Canopy reported a loss of C$0.07 per share, wider than the C$0.02 consensus loss, while revenue also came in below estimates. The earnings miss prompted reports of a sharp decline in the shares. Shares fall after earnings miss
• Negative Sentiment: A $35.8 million charge contributed to the reported loss, and margins weakened as Canadian medical reimbursement fell, tempering the positive revenue trend. Q2 earnings call transcript

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CGC. Weiss Ratings cut shares of Canopy Growth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 16th. Wall Street Zen lowered shares of Canopy Growth from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Canopy Growth has an average rating of “Hold”.

About Canopy Growth

Canopy Growth Corporation is a cannabis company headquartered in Smiths Falls, Ontario, Canada. Founded in 2013, the company operates in the production, distribution and sale of cannabis and cannabis-related products for adult-use and medical markets.

Its product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes, beverages and edibles. Canopy Growth markets products under several brands, including Tweed, 7ACRES, Doja and Deep Space, with offerings designed for different consumer preferences and product segments.

Canopy Growth primarily serves the Canadian recreational and medical cannabis markets and has pursued international opportunities in selected medical-cannabis markets.